Quantum-Si incorporated

NASDAQ:QSI

Biotechnology

Healthcare
$1.01 +5.02%

+$0.05 today

Market cap
$201.80M
Beta
3.17
P/E (TTM)
-2.1
EPS (TTM)
-$0.48
52W Low $0.69High $3.10

Volume 5.35M

Average 5.64M

Big Five Numbers

Quantum-Si incorporated growth analysis

Start with the long-run numbers that show whether QSI compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/A-20.3%
Equity
N/AN/A-24.4%-26.0%
Cash
N/AN/A-36.5%-56.1%
ROIC
N/A-36.2%-42.8%-43.4%

Analysis

Latest growth is strongest in Revenue at -20.3% and weakest in Cash at -56.1%. Three-year average ROIC is -42.8%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+112.6% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +112.6% (5yr), giving you a quick read on expected growth from here.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where QSI earns its revenue, as reported in company filings

  • Product
  • Service
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
Product$2.29M93.8%-21.8%
Service$150K6.2%+12.8%

Figures in USD.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$101.3M
+ D&A$4.5M
+ Stock-Based Comp$10.8M
+ Deferred Tax$0
- Working Capital-$4.6M
- Other Non-Cash-$4.0M
= Operating Cash Flow-$94.7M
- Capex-$2.5M
= Free Cash Flow-$97.2M

Analysis

FY2025 free cash flow is -$97.2M. FCF conversion is 95.9% of net income. Operating cash flow was -$94.7M, with capex of -$2.5M. The largest bridge item is Stock-Based Comp at $10.8M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for QSI.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for QSI.

Sign in free

Competitor growth

How does Quantum-Si incorporated grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

LB Pharmaceuticals Inc Common Stock

LBRX

$1.39B———
—2 analysts

Solid Biosciences Inc.

SLDB

$763.42M———
—5 analysts

Aura Biosciences, Inc.

AURA

$739.97M———
—1 analysts

Annexon, Inc.

ANNX

$642.26M———
—6 analysts

Altimmune, Inc.

ALT

$319.98M-42.6%-65.3%—
+418.3% (5yr)5 analysts

Autolus Therapeutics plc

AUTL

$311.41M+95.2%+113.2%+130.2%
+51.0% (5yr)3 analysts

DBV Technologies S.A.

DBVT

$263.50M———
—2 analysts

Rocket Pharmaceuticals, Inc.

RCKT

$252.48M———
—7 analysts

ADC Therapeutics S.A.

ADCT

$171.07M——-27.1%
+30.5% (5yr)2 analysts

enGene Holdings Inc.

ENGN

$161.51M———
—2 analysts

Questions

Growth questions

Common questions about QSI's growth, answered from reported and forecast figures.

Is QSI growing revenue?

Revenue declined 20.3% year over year, from $3.06M to $2.44M.

Is QSI turning growth into profit?

The latest net margin is -4160.1%, which shows how much revenue became net income.